Nurix Therapeutics, Inc. (NRIX) intrinsic value & 10-year financials
Nurix Therapeutics, Inc. (NRIX) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 8 fiscal years revenue grew 18.0% a year to $84.0M, with an average return on invested capital of -46.2%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $24.42
- Market cap
- $2.1B
- Revenue (FY2025)
- $84.0M
- Revenue growth (8-yr CAGR)
- 18.0%
- ROIC (10-yr avg)
- -46.2%
- Free cash flow (FY2025)
- -$263.5M
NRIX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $84.0M | -$264.5M | -$3.05 | -$263.5M | -340.2% | -73.1% |
| FY2024 | $54.5M | -$193.6M | -$2.88 | -$181.9M | -390.5% | -70.3% |
| FY2023 | $77.0M | -$143.9M | -$2.65 | -$89.8M | -201.4% | -74.8% |
| FY2022 | $38.6M | -$180.4M | -$3.71 | -$172.1M | -476.0% | -71.2% |
| FY2021 | $29.8M | -$117.2M | -$2.73 | -$90.0M | -396.3% | -43.5% |
| FY2020 | $17.8M | -$43.2M | — | -$4.6M | -364.7% | -37.9% |
| FY2019 | $31.1M | -$21.7M | — | -$1.1M | -71.5% | 47.0% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Nurix Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Nurix Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -46.2% ROIC.
Nurix Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Nurix Therapeutics, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-101.31 per share.